HER2-POSITIVE BREAST CANCER
Clinical trials for HER2-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for breast cancer patients: extra drug may wipe out remaining tumor
Disease control Not yet recruitingThis study tests whether adding 4 cycles of the drug T-DXh can eliminate leftover cancer in women with HER2-positive breast cancer who still have disease after standard chemotherapy. About 59 participants will receive T-DXh before surgery. The goal is to see if more patients can …
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE4 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 26, 2026 05:12 UTC
-
New Triple-Drug combo aims to keep advanced breast cancer in check
Disease control Not yet recruitingThis study looks at whether adding pyrotinib to two standard drugs (trastuzumab and pertuzumab) can help keep advanced HER2-positive breast cancer from growing. About 42 adults with this type of cancer will receive the combination as maintenance therapy after initial treatment. T…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 26, 2026 05:10 UTC
-
New hope for hard-to-treat breast cancer: experimental drug takes on standard therapy
Disease control Not yet recruitingThis study compares a new drug, SHR-A1811, with a standard combination therapy (pyrotinib plus capecitabine) in 100 adults with advanced HER2-positive breast cancer that did not respond to the first-line drug trastuzumab. The goal is to see which treatment better delays cancer gr…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 26, 2026 05:04 UTC
-
New combo therapies aim to keep advanced breast cancer in check
Disease control Not yet recruitingThis study tests whether combining different drugs after an initial treatment can help control advanced HER2-positive breast cancer for longer. About 288 women with cancer that has spread or cannot be removed will receive either trastuzumab plus pyrotinib or trastuzumab plus dalp…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 26, 2026 05:03 UTC
-
New theranostic approach targets brain metastases in solid tumors
Disease control Not yet recruitingThis study tests special drugs that can both find and treat cancer that has spread to the brain. About 10 adults with advanced breast cancer or other solid tumors will receive a radioactive agent to see if it reaches the brain tumors and helps shrink them. The goal is to measure …
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated May 26, 2026 05:02 UTC
-
New combo therapy targets breast cancer brain tumors
Disease control Not yet recruitingThis early-phase study tests a drug called trastuzumab deruxtecan (T-DXd) combined with precise radiation (SRS) for people with HER2-positive breast cancer that has spread to the brain. The goal is to find the safest dose of the drug when given with radiation and to see how well …
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New hope for advanced breast cancer: experimental combo enters phase 3 trial
Disease control Not yet recruitingThis phase 3 trial tests a new drug, BL-M07D1, combined with pertuzumab against the standard treatment (docetaxel, trastuzumab, and pertuzumab) in 596 women with HER2-positive breast cancer that has spread or returned. The goal is to see if the new combo delays cancer growth or i…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
New hope for HER2+ breast cancer patients who stopped responding to previous therapy
Disease control Not yet recruitingThis study tests a new drug combination (RC48 plus chemotherapy) against standard treatment (trastuzumab or inetetamab plus chemo) in people with HER2-positive advanced breast cancer whose disease worsened or who couldn't tolerate a prior type of antibody-drug conjugate. About 26…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2, PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New hope for breast cancer patients with brain tumors: drug combo enters trial
Disease control Not yet recruitingThis phase 2 trial tests whether adding neratinib to the standard drug trastuzumab deruxtecan helps control HER2-positive breast cancer that has spread to the brain. About 202 women aged 18-70 will be randomly assigned to one of two treatment groups. The goal is to see if the com…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Could breast cancer treatment skip surgery? new trial explores non-surgical path
Disease control Not yet recruitingThis study tests whether some people with early-stage breast cancer can safely avoid surgery after chemotherapy and radiation. Participants will be monitored with MRIs, mammograms, and blood tests to check if the cancer stays away. The goal is to see if a non-surgical approach wo…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New pill aims to stop dangerous platelet drop in breast cancer treatment
Prevention Not yet recruitingThis study tests whether the drug herombopag can prevent low platelet counts (thrombocytopenia) in people with HER2-positive breast cancer receiving T-DM1 therapy. Low platelets are common in Asian patients and can cause bleeding or force treatment delays. About 45 participants w…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: NA • Sponsor: Zhenzhen Liu • Aim: Prevention
Last updated May 18, 2026 12:01 UTC